Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cross Iron: IV vs Oral Iron with Epoetin Alfa for Preoperative Anemia
NCT02496377Completed
- Sponsor
- CHU Montpellier
- Start
- Aug 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ferric carboxymaltose in anemia, sponsored by CHU Montpellier. Primary endpoint: Change in Hemoglobin level. Started Aug 2014; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
anemia
Beyond the preview
Go deeper on NCT02496377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496377.